Vaccination: adverse effects
Advantages and disadvantages of immunization prior to the vaccination should be weighed carefully. For this purpose you should seek advice from your doctor.
In these cases, vaccines are not recommended or restricted:
During pregnancy should not be dispensed with much needed vaccinations.Vaccination with live vaccines against yellow fever, measles, mumps, rubella andchicken pox should not be performed.
For at least two weeks after an acute illness requiring treatment should normally not be vaccinated. Otherwise adverse effects of vaccination may threaten. Exceptions vaccines, which are performed after the patient had beenexposed to a pathogen (post-exposure adverse effects of vaccination) are.
Have occurred in temporal relation to a previous vaccination adverse drug effects, they must again before vaccination with the same vaccine should be clarified.
If allergies to components of vaccines (for example, egg white) are known for the vaccine may not be used in vaccines that contain these ingredients.
Saturday 10 December 2011
adverse effects of Lumiracoxib prexige(R)
Lumiracoxib: withdrawal because of severe liver injury in Australia / Germany: Limitations of Use
The Australian TGA and Drug Administration has ordered the withdrawal of lumiracoxib. The reasons for this decision by the TGA, was that there were five reported cases of liver failure associated with use of lumiracoxib and three more such cases from South America. In two cases, the liver injury was fatal, and in two other cases had a liver transplant. Lumiracoxib-containing medicines in Australia, with 100 mg and 200 mg of active ingredient per tablet for the symptomatic treatment of osteoarthritis (degenerative joint disease) or with 400 mg of active compound for the treatment of acute pain was admitted.
Lumiracoxib is a compound from the group of coxibs and is used for its anti-inflammatory and analgesic effect for the symptomatic treatment of osteoarthritis and acute pain. In the European Union including Germany lumiracoxib is also allowed, but only in one tablet strength and daily dose of 100 mg lumiracoxib and only for treatment of symptoms in osteoarthritis of the knee and hip joints, but due to adverse effects not for the treatment of other acute pain.
The newly reported cases of liver failure occurred almost exclusively on the application of the higher dose of lumiracoxib 200 mg and 400 mg per day. There are some adverse effects of lumiracoxib known. From the conducted prior to approval clinical trials showed that lumiracoxib may result in a dose-dependent increase in the activity of certain liver enzymes (transaminases) in the blood. This was one of the reasons for which high-dose lumiracoxib in the treatment of acute pain in the EU was not approved. Overall, before the BfArM few reports of liver dysfunction after lumiracoxib application, severe liver damage (liver failure) from Germany and the EU have not been previously reported.
The Australian TGA and Drug Administration has ordered the withdrawal of lumiracoxib. The reasons for this decision by the TGA, was that there were five reported cases of liver failure associated with use of lumiracoxib and three more such cases from South America. In two cases, the liver injury was fatal, and in two other cases had a liver transplant. Lumiracoxib-containing medicines in Australia, with 100 mg and 200 mg of active ingredient per tablet for the symptomatic treatment of osteoarthritis (degenerative joint disease) or with 400 mg of active compound for the treatment of acute pain was admitted.
Lumiracoxib is a compound from the group of coxibs and is used for its anti-inflammatory and analgesic effect for the symptomatic treatment of osteoarthritis and acute pain. In the European Union including Germany lumiracoxib is also allowed, but only in one tablet strength and daily dose of 100 mg lumiracoxib and only for treatment of symptoms in osteoarthritis of the knee and hip joints, but due to adverse effects not for the treatment of other acute pain.
The newly reported cases of liver failure occurred almost exclusively on the application of the higher dose of lumiracoxib 200 mg and 400 mg per day. There are some adverse effects of lumiracoxib known. From the conducted prior to approval clinical trials showed that lumiracoxib may result in a dose-dependent increase in the activity of certain liver enzymes (transaminases) in the blood. This was one of the reasons for which high-dose lumiracoxib in the treatment of acute pain in the EU was not approved. Overall, before the BfArM few reports of liver dysfunction after lumiracoxib application, severe liver damage (liver failure) from Germany and the EU have not been previously reported.
adverse effects of dronedarone
Rebuilding value of antiarrhythmic therapy for atrial fibrillation by improving forecast. Note the adverse effects of dronedarone described.
Proven for over 500 days of the antiarrhythmic agent dronedarone in Germany in Practice: antiarrhythmic drug dronedarone as a first for non-permanent atrial fibrillation studies, a reduction in cardiovascular hospitalizations or death from any cause shown. This led to the recommendation of the European Society of Cardiology (European Society of Cardiology, ESC). Dronedarone was as a treatment option of choice for the maintenance of sinus rhythm in patients with non-permanent atrial fibrillation (AF) (except for patients with chronic heart failure NYHA class III / IV or unstable - decompensation within the last month - heart failure NYHA class II) included in the ESC guidelines.
• antiarrhythmic drug dronedarone reduced first cardiovascular-related hospitalizations or death from any cause
• As a first-line therapy in patients with non-permanent AF in the ESC guidelines included
• Quality of life and avoidance of hospitalization as new therapeutic target in the ESC guidelines
In addition, the guidelines recommend a single antiarrhythmic drug dronedarone to reduce cardiovascular hospitalizations in patients with non-permanent AF and cardiovascular risk factors. (1) in Germany were treated over 70,000 patients since approval of dronedarone (Multaq ®). "The treatment histories allow important conclusions for the future proper use in practice, explained Prof. Dr. Dieter pair, Director of Medical and Scientifc Affairs at Sanofi-Aventis Germany GmbH during the press conference the company on 9 June 2011 in Frankfurt am Main. "The correct use of dronedarone in patients for whom it is suitable, we continue to be a very important concern," said pair. "We have therefore supported by the doctors at the start of the therapy management of patients: not only with the technical information but also with an information card to the most important security-related topics. . This allows the attending physician a quick overview on the proper use of dronedarone adverse effects, interactions, cautions, and additional warnings and recommendations, "At the same time, the clinical research program will continue to dronedarone: The multinational, randomized, double-blind, Phase IIIb study Pallas is said to more than 10,000 patients with permanent atrial fibrillation, the potential clinical benefit of dronedarone in the reduction of major cardiovascular adverse effects events assessed. (2)
Saturday 26 November 2011
Subscribe to:
Posts (Atom)